Jardiance® (empagliflozin) Phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease
OXFORD, England & INGELHEIM, Germany & INDIANAPOLIS--(BUSINESS WIRE)--The EMPA-KIDNEY trial, evaluating the effect of empagliflozin in adults with chronic kidney disease (CKD), will sto......
